St. Francis Hospital’s dedicated team of neurointerventionalists are on the front line in the treating ischemic stroke, using technology scarcely found elsewhere on Long Island. Stroke is the fifth leading cause of death in the U.S., and sadly even its survivors often never recover fully. That’s because millions of neurons start to die the moment stroke occurs, making timely intervention so critical. Stroke patients at St. Francis Hospital are initially issued tissue plasminogen activator (TPA), an IV medication that works locally to break up a clot. But should that fail, lead interventional Jeffrey Farkas, M.D., and his colleagues quickly admit the patient to St. Francis’s catheterization lab to visualize the clot and literally pull it out. Neurointerventionalists open the blood vessel and restore blood flow to the brain. It’s not surgery – it’s a purely endovascular approach. Guided by X-ray and angiogram, specialists in neurointervention thread micro-catheters through blood vessels to locate blood clots and dissolve or remove them.
Neurointervention is the first major advance in stroke treatment since TPA was FDA approved in 1995. In just the last two years, neurointervention has become the standard of care in the treatment of stroke, cerebral aneurysm, and other adverse vascular conditions of the head, neck and spine. While TPA remains an important agent in caring for stroke patients, St. Francis Hospital’s neurointervention team provides stroke patients the best care currently available.
St. Francis Hospital's Neurointerventionalists:
Jeffrey Farkas, M.D.
David Turkel-Parrella, M.D.
Karthikeyan M. Arcot, M.D.
Learn more about Neurointervention: